Gilead Unveils New Data on PBC and Hepatitis Treatments at EASL 2026
Event summary
- Gilead will present 29 abstracts, including late-breaking data, at EASL 2026 in Barcelona from May 27-30, 2026.
- New data on Livdelzi (seladelpar) for primary biliary cholangitis (PBC) includes Phase 3 RESPONSE and ASSURE trial results.
- Bulevirtide, an investigational treatment for hepatitis delta virus (HDV), shows promising safety and efficacy data across diverse patient populations.
- Gilead highlights progress in HBV cure research and HCV elimination efforts.
The big picture
Gilead's presentation at EASL 2026 underscores its leadership in liver disease treatments, particularly in PBC and viral hepatitis. The company's focus on advancing Livdelzi and bulevirtide aligns with broader industry trends toward targeted therapies and personalized medicine. The strategic significance lies in Gilead's ability to leverage these data to strengthen its market position and drive future growth in the liver disease space.
What we're watching
- Regulatory Approval
- Whether Livdelzi's accelerated approval will be confirmed based on upcoming trial results.
- Market Expansion
- The pace at which Gilead can expand Livdelzi's use in broader PBC populations.
- Competitive Dynamics
- How Gilead's data on bulevirtide will position it against existing HDV treatments.
Related topics